Overview
Fievel Lim, Michael Green, and John Molenda authored the article "What Data Says About Biologics-Related Ex Parte Challenges," which was recently published in Law360. This article provides a comprehensive look at over a decade of Ex Parte Reexamination (EPR) activity involving biologics‑related patents. It is a companion piece to their publication earlier in the year concerning biologics related IPRs and PGRs entitled "Checking In On Biologics-Related Patent Review Trends." This new article analyzes nearly 70 EPR requests and explores filing patterns, institution trends, and merits outcomes, while also assessing how recent PTO policy shifts may affect future challenges.
